Genetic evidence supporting fibroblast growth factor 21 signalling as a pharmacological target for cardiometabolic outcomes and Alzheimer's disease

Larsson, Susanna C; Gill, Dipender

doi:https://www.dx.doi.org/10.3390/nu13051504

File(s)

Genetic Evidence Supporting Fibroblast Growth Factor 21 Signalling as a Pharmacological Target for Cardiometabolic Outcomes .pdf (3.06 MB)

Published version

Author(s)

Larsson, Susanna C

Gill, Dipender

Type

Journal Article

Abstract

Fibroblast growth factor 21 (FGF21) is a human metabolic hormone whose effects include modification of macronutrient preference and energy homeostasis. In animal models, FGF21 has been shown to have beneficial effects on cardiometabolic outcomes, Alzheimer’s disease risk and lifespan. In this study, the single-nucleotide polymorphism rs838133 in the FGF21 gene region was leveraged to investigate the potential clinical effects of targeting FGF21. The FGF21 G allele was associated with lower intakes of total sugars and alcohol, and higher intakes of protein and fat as well as favourable with lipid levels, blood pressure traits, waist-to-hip ratio, systemic inflammation, cardiovascular outcomes, Alzheimer’s disease risk and lifespan. These findings may be used to anticipate the effects of pharmacologically increasing FGF21 signalling.

Date Issued

2021-05-01

Date Acceptance

2021-04-25

Citation

Nutrients, 2021, 13 (5), pp.1-5

URI

http://hdl.handle.net/10044/1/94510

URL

https://www.mdpi.com/2072-6643/13/5/1504

DOI

https://www.dx.doi.org/10.3390/nu13051504

ISSN

2072-6643

Publisher

MDPI AG

Start Page

1

End Page

5

Journal / Book Title

Nutrients

Volume

13

Issue

5

Copyright Statement

© 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

License URL

http://creativecommons.org/licenses/by/4.0/

Identifier

http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000662433700001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Subjects

Science & Technology

Life Sciences & Biomedicine

Nutrition & Dietetics

alcohol

cardiovascular disease

fibroblast growth factor 21

macronutrients

sugar

mendelian randomization

SUGAR INTAKE

FGF21

SWEET

PREFERENCE

Publication Status

Published

Article Number

ARTN 1504

Date Publish Online

2021-04-29